Form 8-K Dare Bioscience, Inc. For: Jul 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
Dare Bioscience faces Nasdaq delisting over equity deficiency
July 17, 2026 4:10 PM EDTDare Biosciences, Inc. (NASDAQ: DARE) received a notification from Nasdaq's Listing Qualifications Staff on July 13, 2026, stating that the company no longer complies with Nasdaq Listing Rule 5550(b).
According to the company's Form 10-Q for the period ended March 31, 2026, stockholders' equity fell below the required... More
